Summary

The global market for Hospital-Acquired Pneumonia Prevention was estimated to be worth US$ 178 million in 2024 and is forecast to a readjusted size of US$ 276 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Dental plaque is a biofilm formed by bacteria and their excreta, mainly distributed between the gums, and these bacteria cannot be removed using gauze or sponges. Bacteria in the mouth will quickly form a bacterial biofilm and cover the surface of the teeth within two hours after each cleaning. This biofilm protects common pathogens in the ICU, such as Staphylococcus aureus and Klebsiella pneumoniae. This biofilm must be destroyed before using antibacterial agents. If plaque and bacteria cannot be removed, they will move down to the balloon of the endotracheal tube. Since the balloon sealing cannot reach 100%, aspiration pneumonia will occur. Oral care is one of the effective means to prevent hospital-acquired pneumonia.
In hospitals, oral care is a vital measure to prevent aspiration pneumonia (i.e., hospital-acquired pneumonia), especially for bedridden patients, the elderly, patients with weakened immunity, and critically ill patients. This is because if the bacteria in the mouth are not effectively removed, they may enter the lungs through aspiration (i.e., swallowing saliva, food, or oral secretions), thus causing pneumonia. With the advancement of medical technology and the improvement of patients' awareness of hospital infection prevention and control, the prevention measures of hospital-acquired pneumonia have gradually gained attention. Globally, the prevention market of hospital-acquired pneumonia has gradually developed with the changes in public health needs and medical environment. The prevention market of hospital-acquired pneumonia included in this report is mainly oral care products.
Oral care products usually include oral care kits, moisturizing gels, mouthwashes, etc., among which oral care kits accounts for the largest proportion.
From the application point of view, patients in intensive care units (ICUs) are usually in an immunosuppressive state, and the risk of pneumonia infection is higher than that of patients in ordinary wards. Oral care has become an important part of reducing infection and preventing pneumonia. In order to reduce the incidence of hospital-acquired pneumonia in ICU patients, the use of oral care kits has become one of the standard preventive measures. The proportion in 2023 is approximately 60%.
The global key players of HAP prevention include Stryker, Medline, Ecolab, Avanos, Dentsply Sirona, Intersurgical and Dentaid, etc. In 2023, in term of revenue of HAP prevention, the top 3 companies hold a share nearly 43%.
The problem of antibiotic resistance is becoming more and more serious, and traditional antibiotic treatment is no longer the only way to deal with hospital-acquired pneumonia. Preventive measures, such as the use of oral care kits, can effectively reduce bacterial loads and reduce the need for antibiotics, thereby alleviating the problem of drug resistance.
This report aims to provide a comprehensive presentation of the global market for Hospital-Acquired Pneumonia Prevention, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Hospital-Acquired Pneumonia Prevention by region & country, by Type, and by Application.
The Hospital-Acquired Pneumonia Prevention market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital-Acquired Pneumonia Prevention.
Market Segmentation
By Company
Stryker
Medline
Ecolab
Avanos
Dentsply Sirona
Intersurgical
Dentaid
Xttrium
Germiphene
Segment by Type
Oral Care Kit
Moisturizer Gel
Mouth Wash
Others
Segment by Application
General Ward
Intensive Care Unit
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Hospital-Acquired Pneumonia Prevention manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Hospital-Acquired Pneumonia Prevention in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Hospital-Acquired Pneumonia Prevention in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Hospital-Acquired Pneumonia Prevention Product Introduction
1.2 Global Hospital-Acquired Pneumonia Prevention Market Size Forecast
1.2.1 Global Hospital-Acquired Pneumonia Prevention Sales Value (2020-2031)
1.2.2 Global Hospital-Acquired Pneumonia Prevention Sales Volume (2020-2031)
1.2.3 Global Hospital-Acquired Pneumonia Prevention Sales Price (2020-2031)
1.3 Hospital-Acquired Pneumonia Prevention Market Trends & Drivers
1.3.1 Hospital-Acquired Pneumonia Prevention Industry Trends
1.3.2 Hospital-Acquired Pneumonia Prevention Market Drivers & Opportunity
1.3.3 Hospital-Acquired Pneumonia Prevention Market Challenges
1.3.4 Hospital-Acquired Pneumonia Prevention Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Hospital-Acquired Pneumonia Prevention Players Revenue Ranking (2024)
2.2 Global Hospital-Acquired Pneumonia Prevention Revenue by Company (2020-2025)
2.3 Global Hospital-Acquired Pneumonia Prevention Players Sales Volume Ranking (2024)
2.4 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Company Players (2020-2025)
2.5 Global Hospital-Acquired Pneumonia Prevention Average Price by Company (2020-2025)
2.6 Key Manufacturers Hospital-Acquired Pneumonia Prevention Manufacturing Base and Headquarters
2.7 Key Manufacturers Hospital-Acquired Pneumonia Prevention Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Hospital-Acquired Pneumonia Prevention
2.9 Hospital-Acquired Pneumonia Prevention Market Competitive Analysis
2.9.1 Hospital-Acquired Pneumonia Prevention Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Hospital-Acquired Pneumonia Prevention Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital-Acquired Pneumonia Prevention as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral Care Kit
3.1.2 Moisturizer Gel
3.1.3 Mouth Wash
3.1.4 Others
3.2 Global Hospital-Acquired Pneumonia Prevention Sales Value by Type
3.2.1 Global Hospital-Acquired Pneumonia Prevention Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Hospital-Acquired Pneumonia Prevention Sales Value, by Type (2020-2031)
3.2.3 Global Hospital-Acquired Pneumonia Prevention Sales Value, by Type (%) (2020-2031)
3.3 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Type
3.3.1 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Hospital-Acquired Pneumonia Prevention Sales Volume, by Type (2020-2031)
3.3.3 Global Hospital-Acquired Pneumonia Prevention Sales Volume, by Type (%) (2020-2031)
3.4 Global Hospital-Acquired Pneumonia Prevention Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 General Ward
4.1.2 Intensive Care Unit
4.2 Global Hospital-Acquired Pneumonia Prevention Sales Value by Application
4.2.1 Global Hospital-Acquired Pneumonia Prevention Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Hospital-Acquired Pneumonia Prevention Sales Value, by Application (2020-2031)
4.2.3 Global Hospital-Acquired Pneumonia Prevention Sales Value, by Application (%) (2020-2031)
4.3 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Application
4.3.1 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Hospital-Acquired Pneumonia Prevention Sales Volume, by Application (2020-2031)
4.3.3 Global Hospital-Acquired Pneumonia Prevention Sales Volume, by Application (%) (2020-2031)
4.4 Global Hospital-Acquired Pneumonia Prevention Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Hospital-Acquired Pneumonia Prevention Sales Value by Region
5.1.1 Global Hospital-Acquired Pneumonia Prevention Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Hospital-Acquired Pneumonia Prevention Sales Value by Region (2020-2025)
5.1.3 Global Hospital-Acquired Pneumonia Prevention Sales Value by Region (2026-2031)
5.1.4 Global Hospital-Acquired Pneumonia Prevention Sales Value by Region (%), (2020-2031)
5.2 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Region
5.2.1 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Region (2020-2025)
5.2.3 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Region (2026-2031)
5.2.4 Global Hospital-Acquired Pneumonia Prevention Sales Volume by Region (%), (2020-2031)
5.3 Global Hospital-Acquired Pneumonia Prevention Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
5.4.2 North America Hospital-Acquired Pneumonia Prevention Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
5.5.2 Europe Hospital-Acquired Pneumonia Prevention Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
5.6.2 Asia Pacific Hospital-Acquired Pneumonia Prevention Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
5.7.2 South America Hospital-Acquired Pneumonia Prevention Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
5.8.2 Middle East & Africa Hospital-Acquired Pneumonia Prevention Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Hospital-Acquired Pneumonia Prevention Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Hospital-Acquired Pneumonia Prevention Sales Value and Sales Volume
6.2.1 Key Countries/Regions Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
6.2.2 Key Countries/Regions Hospital-Acquired Pneumonia Prevention Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
6.3.2 United States Hospital-Acquired Pneumonia Prevention Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Hospital-Acquired Pneumonia Prevention Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
6.4.2 Europe Hospital-Acquired Pneumonia Prevention Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Hospital-Acquired Pneumonia Prevention Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
6.5.2 China Hospital-Acquired Pneumonia Prevention Sales Value by Type (%), 2024 VS 2031
6.5.3 China Hospital-Acquired Pneumonia Prevention Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
6.6.2 Japan Hospital-Acquired Pneumonia Prevention Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Hospital-Acquired Pneumonia Prevention Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
6.7.2 South Korea Hospital-Acquired Pneumonia Prevention Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Hospital-Acquired Pneumonia Prevention Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
6.8.2 Southeast Asia Hospital-Acquired Pneumonia Prevention Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Hospital-Acquired Pneumonia Prevention Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Hospital-Acquired Pneumonia Prevention Sales Value, 2020-2031
6.9.2 India Hospital-Acquired Pneumonia Prevention Sales Value by Type (%), 2024 VS 2031
6.9.3 India Hospital-Acquired Pneumonia Prevention Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Stryker
7.1.1 Stryker Company Information
7.1.2 Stryker Introduction and Business Overview
7.1.3 Stryker Hospital-Acquired Pneumonia Prevention Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Stryker Hospital-Acquired Pneumonia Prevention Product Offerings
7.1.5 Stryker Recent Development
7.2 Medline
7.2.1 Medline Company Information
7.2.2 Medline Introduction and Business Overview
7.2.3 Medline Hospital-Acquired Pneumonia Prevention Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Medline Hospital-Acquired Pneumonia Prevention Product Offerings
7.2.5 Medline Recent Development
7.3 Ecolab
7.3.1 Ecolab Company Information
7.3.2 Ecolab Introduction and Business Overview
7.3.3 Ecolab Hospital-Acquired Pneumonia Prevention Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Ecolab Hospital-Acquired Pneumonia Prevention Product Offerings
7.3.5 Ecolab Recent Development
7.4 Avanos
7.4.1 Avanos Company Information
7.4.2 Avanos Introduction and Business Overview
7.4.3 Avanos Hospital-Acquired Pneumonia Prevention Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Avanos Hospital-Acquired Pneumonia Prevention Product Offerings
7.4.5 Avanos Recent Development
7.5 Dentsply Sirona
7.5.1 Dentsply Sirona Company Information
7.5.2 Dentsply Sirona Introduction and Business Overview
7.5.3 Dentsply Sirona Hospital-Acquired Pneumonia Prevention Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Dentsply Sirona Hospital-Acquired Pneumonia Prevention Product Offerings
7.5.5 Dentsply Sirona Recent Development
7.6 Intersurgical
7.6.1 Intersurgical Company Information
7.6.2 Intersurgical Introduction and Business Overview
7.6.3 Intersurgical Hospital-Acquired Pneumonia Prevention Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Intersurgical Hospital-Acquired Pneumonia Prevention Product Offerings
7.6.5 Intersurgical Recent Development
7.7 Dentaid
7.7.1 Dentaid Company Information
7.7.2 Dentaid Introduction and Business Overview
7.7.3 Dentaid Hospital-Acquired Pneumonia Prevention Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Dentaid Hospital-Acquired Pneumonia Prevention Product Offerings
7.7.5 Dentaid Recent Development
7.8 Xttrium
7.8.1 Xttrium Company Information
7.8.2 Xttrium Introduction and Business Overview
7.8.3 Xttrium Hospital-Acquired Pneumonia Prevention Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Xttrium Hospital-Acquired Pneumonia Prevention Product Offerings
7.8.5 Xttrium Recent Development
7.9 Germiphene
7.9.1 Germiphene Company Information
7.9.2 Germiphene Introduction and Business Overview
7.9.3 Germiphene Hospital-Acquired Pneumonia Prevention Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Germiphene Hospital-Acquired Pneumonia Prevention Product Offerings
7.9.5 Germiphene Recent Development
8 Industry Chain Analysis
8.1 Hospital-Acquired Pneumonia Prevention Industrial Chain
8.2 Hospital-Acquired Pneumonia Prevention Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Hospital-Acquired Pneumonia Prevention Sales Model
8.5.2 Sales Channel
8.5.3 Hospital-Acquired Pneumonia Prevention Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer